TINJAUAN KIMIA FARMASI TERHADAP KARAKTERISTIK FARMASETIKA DAN EVALUASI DISOLUSI TABLET KOMBINASI AMLODIPIN BESILAT – LOSARTAN KALIUM
Abstract
Penggunaan kombinasi obat amlodipin besilat dan losartan kalium pasien hipertensi bertujuan untuk menggantikan terapi tunggal yang kurang efektif. Sediaan kombinasi amlodipin besilat dan losartan kalium dikembangkan untuk memberikan efek sinergis dan meningkatkan kepatuhan pengobatan pasien hipertensi. Tujuan kajian artikel ini yaitu untuk mengetahui kombinasi tablet amlodipin besilat dan losartan kalium pada pasien hipertensi dari sisi farmakologi dan farmasetika. Metode yang digunakan dalam penelitian ini adalah pencarian artikel melalui database tunggal, yaitu Google Scholar. Kombinasi amlodipin besilat dan losartan kalium banyak digunakan pada pasien hipertensi stage II. Penggunaan amlodipin besilat dikombinasi dengan losartan dapat menurunkan tekanan darah secara signifikan dibandingkan penggunaan amlodipin secara monoterapi. Tablet lepas segera lapis ganda dipilih pada kombinasi kedua obat ini karena amlodipin besilat dan losartan kalium memiliki karakteristik yang berbeda, dimana formulasi amlodipin besilat tablet menggunakan kempa langsung dan losartan kalium menggunakan metode granulasi basah. Setelah pembuatan formulasi tablet kombinasi maka dilakukan evaluasi salah satunya uji disolusi. Uji disolusi dilakukan menggunakan alat disolusi USP Tipe II (tipe Paddle).
References
Evbayekha EO, Okobi OE, Okobi T, Ibeson EC, Nwafor JN, Ozobokeme O emi, et al. The Evolution of Hypertension Guidelines Over the Last 20+ Years: A Comprehensive Review. Cureus [Internet]. 2022 Nov 13; Available from: https://www.cureus.com/articles/120980-the-evolution-of-hypertension-guidelines-over-the-last-20-years-a-comprehensive-review
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.
Dybiec J, Krzemińska J, Radzioch E, Szlagor M, Wronka M, Młynarska E, et al. Advances in the Pathogenesis and Treatment of Resistant Hypertension. Int J Mol Sci. 2023;24(16).
Messerli, Franz H; Williams, Bryan; Ritz E. Essential Hypertension. Br Med J. 2007;1(5282):945.
Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Prim [Internet]. 2018 Mar 22;4(1):18014. Available from: https://www.nature.com/articles/nrdp201814
Laurent S. Antihypertensive drugs. Pharmacol Res [Internet]. 2017 Oct;124:116–25. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1043661817308460
Marinier K, Macouillard P, de Champvallins M, Deltour N, Poulter N, Mancia G. Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2019;28(12):1572–82.
Smith DK, Lennon RP, Carlsgaard PB. Managing Hypertension Using Combination Therapy. Am Fam Physician [Internet]. 2020 Mar 15;101(6):341–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32163253
Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–31.
Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S, et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination. Medicine (Baltimore). 2016;95(30):e4071.
Kim SH, Ryu KH, Lee NH, Kang JH, Kim WS, Park SW, et al. Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: A randomized, double blind, multicenter study. BMC Res Notes. 2011;4.
Tiwaskar M, Langote A, Kashyap R, Toppo A. Amlodipine in the Era of New Generation Calcium Channel Blockers. J Assoc Physicians India [Internet]. 2018 Mar;66(3):64–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30341872
Wang JG, Palmer BF, Vogel Anderson K, Sever P. Amlodipine in the current management of hypertension. J Clin Hypertens. 2023;25(9):801–7.
Bulsara KG, Patel P, Cassagnol M. Amlodipine [Internet]. StatPearls. 2024. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22429432
McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther [Internet]. 1997 Jan;74(2):181–94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0163725897820025
Al-Majed ARA, Assiri E, Khalil NY, Abdel-Aziz HA. Losartan. In 2015. p. 159–94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1871512515000084
Tolou Ghamari Z. Losartan: A Pharmacotherapy in Cardiovascular Disease. New Emirates Med J [Internet]. 2023 Oct 6;5. Available from: https://www.eurekaselect.com/219529/article
Bezerra EM, de Alvarenga ÉC, dos Santos RP, de Sousa JS, Fulco UL, Freire VN, et al. Losartan as an ACE inhibitor: a description of the mechanism of action through quantum biochemistry. RSC Adv [Internet]. 2022;12(44):28395–404. Available from: https://xlink.rsc.org/?DOI=D2RA04340H
Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al. Losartan in Heart Failure. Circulation [Internet]. 1995 Feb;91(3):691–7. Available from: https://www.ahajournals.org/doi/10.1161/01.CIR.91.3.691
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet [Internet]. 2009 Nov;374(9704):1840–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673609619139
Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther [Internet]. 2000 Oct;22(10):1186–203. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0149291800830623
Hong BK, Park CG, Kim KS, Yoon MH, Yoon HJ, Yoon JH, et al. Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan. Am J Cardiovasc Drugs [Internet]. 2012 Jun;12(3):189–95. Available from: http://link.springer.com/10.2165/11597410-000000000-00000
He DH, Zhang LM, Lin LM, Ning RB, Wang HJ, Xu CS, et al. Effects of losartan and amlodipine on left ventricular remodeling and function in young stroke-prone spontaneously hypertensive rats. Acta Cardiol Sin. 2014;30(4):316–24.
Kang SM, Youn JC, Chae SC, Park CG, Yang JY, Kim MH, et al. Comparative Efficacy and Safety Profile of Amlodipine 5 mg/Losartan 50 mg Fixed-Dose Combination and Amlodipine 10 mg Monotherapy in Hypertensive Patients Who Respond Poorly to Amlodipine 5 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind . Clin Ther. 2011;33(12):1953–63.
Choi YJ, Lee SH, Cho SM, Kang WH, Nam KY, Jang IJ, et al. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: Arandomized, open-label, single-dose, two-period, two-sequence crossover study. Drug Des Devel Ther [Internet]. 2016;10:3021–8. Available from: https://doi.org/10.2147/DDDT.S113891
Suh SY, Ahn T, Bae JH, Lim DS, Lee SU, Kim YK, et al. Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy. Clin Ther. 2014;36(10):1402–11.
Yoon DY, Park SI, Jung JA, Kim Y Il, Jang IJ, Chung JY. Comparison of pharmacokinetics of a fixed-dose combination of amlodipine/losartan/rosuvastatin with concomitant administration of amlodipine/ losartan and rosuvastatin in healthy volunteers. Drug Des Devel Ther. 2020;14:661–8.
Evagelin MP, Elisha Y, Kumar PP, Lakshmi GS, Arathi K. Design and evaluation of amlodipine and losartan potassium immediate release tablets by direct compression method. J Med Res. 2020;6(3):103–5.
Al Khawaja AY, Khalil EA, Mansour RS, Hamdan II. Preparation, Characterization and Transdermal Permeation of Losartan-Amlodipine Molecular Salt. Jordan J Pharm Sci. 2022;15(4):536–52.
Sawant RL, Raskar MA, Somawanshi GP, Jadhav SA. Simultaneous UV Spectrophotometric methods for estimation of losartan potassium and amlodipine besylate in tablet dosage form. Res J Pharm Biol Chem Sci. 2012;3(3):397–404.
Wankhede SB, Raka KC, Wadkar SB, Chitlange SS. Spectrophotometric and HPLC methods for simultaneous estimation of amlodipine besilate, losartan potassium and hydrochlorothiazide in tablets. Indian J Pharm Sci. 2010;72(1):136–40.
Gray VA, Rosanske TW. Dissolution. Specif Drug Subst Prod Dev Valid Anal Methods, Second Ed. 2020;481–503.
Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018;10(3).
Zaborenko N, Shi Z, Corredor CC, Smith-Goettler BM, Zhang L, Hermans A, et al. First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing. AAPS J. 2019;21(3).
Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, et al. The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations. Curr Issues Mol Biol. 2024;46(7):6315–27.
Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes. Open Hear. 2016;3(2):1–7.
Luo Y, Ren L, Jiang M, Chu Y. Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis. Rev Cardiovasc Med. 2019;20(2):91–8.
Khodadoustan S, Nasri Ashrafi I, Vanaja Satheesh K, Kumar C, Shekar HS, Chikkalingaiah S. Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. Clin Exp Hypertens. 2017;39(6):520–6.
Rabah F, El-Naggari M, Al-Nabhani D. Amlodipine: The double edged sword. J Paediatr Child Health. 2017;53(6):540–2.
Cavusoglu T, Karadeniz T, Cagiltay E, Karadeniz M, Yigitturk G, Acikgoz E, et al. The Protective Effect of Losartan on Diabetic Neuropathy in a Diabetic Rat Model. Exp Clin Endocrinol Diabetes. 2015;123(8):479–84.
Katsiki N, Tsioufis K, Ural D, Volpe M. Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)—Lessons learned for losartan: An “old dog playing good tricks.” J Clin Hypertens. 2018;20(8):1153–9.
Fan Y, Wei F, Lang Y, Wang S. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: Ameta-analysis. J Hypertens. 2015;33(4):681–9.
Kalikar M, Nivangune K, Dakhale G, Bajait C, Sontakke S, Motghare V, et al. Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage i hypertension: A randomized, open-label study. J Pharmacol Pharmacother. 2017;8(3):106–11.
Tiwari RN, Shah N, Bhalani V, Mahajan A. LC, MSn and LC-MS/MS studies for the characterization of degradation products of amlodipine. J Pharm Anal [Internet]. 2015;5(1):33–42. Available from: http://dx.doi.org/10.1016/j.jpha.2014.07.005
Sodeifian G, Garlapati C, Razmimanesh F, Sodeifian F. Solubility of amlodipine besylate (calcium channel blocker drug) in supercritical carbon dioxide: Measurement and correlations. J Chem Eng Data. 2021;66(2):1119–31.
Silva ACM, Gálico DA, Guerra RB, Perpétuo GL, Legendre AO, Rinaldo D, et al. Thermal stability and thermal decomposition of the antihypertensive drug amlodipine besylate. J Therm Anal Calorim. 2015;120(1):889–92.
Kumar TH, Asha C, Sankar DG. Estimation of amlodipine besylate and irbesartan in pharmaceutical formulation by RP-HPLC with forced degradation studies. Int J Appl Pharm. 2019;11(3):159–67.
Koradia V, Lopez De Diego H, Frydenvang K, Ringkjøbing-Elema M, Müllertz A, Bond AD, et al. Solid forms of amlodipine besylate: Physicochemical, structural, and thermodynamic characterization. Cryst Growth Des. 2010;10(12):5279–90.
Jakimska A, ͆liwka-Kaszyńska M, Nagórski P, Namies̈nik J, Kot-Wasik A. Phototransformation of Amlodipine: Degradation Kinetics and Identification of Its Photoproducts. PLoS One. 2014;9(10).
García JA, Bendezú MR, Pineda-Pérez M, Muñoz AM, Saravia M, Alvarado AT. Quality Attributes and In Vitro Bioequivalence of Amlodipine (5 mg) Tablets in Ica, Peru. Dissolution Technol. 2021;28(4):2–11.
Grover I, Agarwal G. Formulation and evaluation of sublingual tablets of lisinopril. J Sci Ind Res (India). 2012;71(6):413–7.
Foley L, Toney J, Barlow JW, O´Connor M, Fitzgeral-Hughes D, Ramtoola Z. Investigation of the Physical , Chemical and Microbiological Liquid Suspension. Molecules. 2021;26:1–9.
Guo K, Yin Q, Yang Y, Zhang M, Wang J. Solubility of losartan potassium in different pure solvents from (293.15 to 343.15) K. J Chem Eng Data. 2008;53(7):1467–9.
Gunda RK, Vijayalakshmi A. Design, formulation, and in vitro evaluation of sustained release tablets for losartan potassium. Drug Invent Today. 2018;10(3):315–21.
Sewar RB, Wafaa Absi K. Bioequivalence of Losartan/Amlodipine Fixed Dose Combination Tablets (Losanet AM) Compared with Concomitant Administration of Single Components of Losartan and Amlodipine Tablets in Healthy Human Volunteers. J Bioequiv Availab. 2015;07(05):216–24.
Park JW, Kim KA, Il Kim Y, Park JY. Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. Basic Clin Pharmacol Toxicol. 2019;125(4):345–52.
Mujawar, N. K, Magdum S.V, Choundikar M. Y. KPAJRM, Sachin.A N. Formulation And Evalution Of Sustained Release Tablet Of Potassium As Antihypertensive Drug. J Drug Deliv Res. 2016;5(4):1–7.
Kumar, Devendra; Gautam, Girendra; Kumar ADS. Design, development and evaluation of fast release bilayer tablets of Antihypertensive drug (Amlodipine besylate and Losartan potassium). Int J Pharm Life Sci. 2019;21(4):437–41.
Tekade, B. W., Jadhao U. T., Thakare V.M. CDG and PVR. Design and in-Vitro Evaluation of Bilayer Tablet Containing Two Incompatible Antihypertensive Drugs. World J Pharm Res. 2017;6(5):1379–89.
Bonepally C, Tripathy B, Mallikarjun V, Rajkumar J, Reddy M, Reddy K. Formulation and Evaluate Sublingual Tablets of Losartan Potassium Using Different Superdisintegrants. NeuroQuantology [Internet]. 2022;20(10):7990–9. Available from: https://www.researchgate.net/profile/Rajkumar-Jampala/publication/363778603_Chandra_Shekhar_Reddy_Bonepally_et_al_Formulation_And_Evaluate_Sublingual_Tablets_Of_Losartan_Potassium_Using_Different_Superdisintegrants_eISSN1303-5150_wwwneuroquantologycom_FOR
Reddy S. Enhancement Of Dissolution Rate And Solubility Of Β -Cyclodextrin As Carrier. World J Pharm Res. 2015;4(12):1314–23.
Alhamdany AT, Abbas AK. Formulation and in vitro evaluation of amlodipine gastroretentive floating tablets using a combination of hydrophilic and hydrophobic polymers. Int J Appl Pharm. 2018;10(6):126–34.
Acharya S, Pandey J, Joshi HP, Parajuli G, Poudel N, Poudel S, et al. Formulation and Evaluation of Gastro Retentive Floating Tablet of Amlodipine Besylate Using Natural Organic Polymers. Int J Appl Pharm. 2022;14(4):227–34.
.png)
